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ABSTRACT 
In recent genome-wide association studies, the extracellular chaperone protein, clusterin, has 
been identified as a newly-discovered risk factor in Alzheimer’s disease. We have examined the 
interactions between human clusterin and the Alzheimer’s disease-associated amyloid-β140 
peptide (Aβ140) which is prone to aggregate into an ensemble of oligomeric intermediates 
implicated in both the proliferation of amyloid fibrils and in neuronal toxicity. Using highly 
sensitive single molecule fluorescence methods, we have found that Aβ140 forms a 
heterogeneous distribution of small oligomers (from dimers to 50mers), all of which interact with 
clusterin to form long-lived, stable complexes. Consequently, clusterin is able to influence 
strongly both the aggregation and disaggregation of Aβ140 by sequestration of the Aβ oligomers. 
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These results not only elucidate the protective role of clusterin but also provide a molecular basis 
for the genetic link between clusterin and Alzheimer’s disease. 
 
INTRODUCTION 
The aggregation of amyloidogenic peptides and proteins is a highly heterogeneous 
process as monomers aggregate in a stepwise manner via a series of oligomeric intermediates to 
form β-sheet-rich fibrillar structures1,2.  These oligomers have been implicated not only in the 
further generation of aggregates but also in the neurotoxicity associated with many 
neurodegenerative diseases1,37. The detection and characterization of the various oligomeric 
intermediates and their interactions with other proteins has proved to be a difficult task for 
ensemble-level techniques as a result of the inherent heterogeneity of the species involved. 
Recently, however, a variety of techniques has been developed to detect and characterize 
molecular interactions at the level of single molecules812. We have applied two forms of such 
techniques to investigate the aggregation and fibril disaggregation processes of the Alzheimer’s 
disease (AD)-associated peptide, amyloid-β140 (Aβ140) and its interactions with clusterin, an 
extracellular chaperone protein which has been found to be colocalized with senile amyloid 
plaques and has recently been genetically associated with AD1316.  
The single molecule techniques that we have utilized are able to detect and characterize 
the ensemble of oligomeric species formed during the self-assembly and disassembly processes 
of Aβ140 and have been implicated in the toxicity associated with AD
1,5,6,17. The first of these 
techniques, confocal two color coincidence detection (cTCCD), uses two spatially overlapped 
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Gaussian laser beams that are combined to create a single confocal volume. cTCCD identifies 
multimolecular species bearing two different types of fluorophores through the observation of 
coincident bursts of fluorescence when they pass through this confocal volume, thus enabling 
oligomeric species to be detected and analyzed8,10.  The number of peptide molecules present in 
each oligomer, denoted the oligomer size, can be measured by comparing the fluorescence 
brightness values of the coincident fluorescence bursts to the brightness values of non-coincident 
(monomeric) bursts. This method is based on the principle that oligomers contain a greater 
number of molecules, and hence fluorophores, than monomers and therefore will emit 
proportionally brighter bursts. In this work, we refer to this metric as the “apparent size” of an 
oligomer since this parameter is determined indirectly from the fluorescence intensity of the 
species (see Methods, Supplementary Methods and Supplementary Figs. 13 for details). 
The second technique is a two-color version of total internal reflection fluorescence 
microscopy (TIRFM), an imaging technique that uses two overlapped lasers of different 
wavelengths to create dual excitation within the imaging field. Species bearing different 
fluorophores deposited onto a surface within this field can be imaged, and the distribution of 
colocalization of fluorescence can be analyzed to give images with detailed information about 
the composition, size and morphology of the species present. (See Methods, Supplementary Fig. 
1, and Supplementary Methods for details of data acquisition and instrumentation).  
In this study, we have combined solution-phase detection by cTCCD with imaging of 
surface-bound species by TIRFM in order to gain insight not only into the aggregation process of 
Aβ140 but also into the interactions between the AD-linked extracellular chaperone, clusterin, 
and the various species populated along the Aβ140 aggregation pathway. 
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RESULTS 
Characterizing the aggregation of Aβ140  
We first used cTCCD to characterize the species formed during the process of Aβ140 
aggregation and disaggregation in the absence of clusterin. To study the aggregation process, 
equimolar quantities of the Aβ140 peptide, labeled with either the HiLyteFluor488 fluorophore 
or the HiLyteFluor647 fluorophore (Anaspec), were mixed and the sample was incubated at pH 
7.4 and 37 C. cTCCD measurements were then made every 2 to 3 h as the peptides aggregated 
and eventually formed amyloid fibrils (Fig. 1a). A series of control experiments revealed that the 
presence of neither fluorophore had any appreciable effect on the bulk aggregation behavior of 
Aβ140, a result in accord with other studies using the same fluorescent peptides
1821 
(Supplementary Fig. 2). Analysis of the distribution of oligomers reveals a variety of soluble 
species, the majority of which are stable for over three hours at the concentrations and 
temperature required for cTCCD characterization (~2550 pM, 21 C). In addition, control 
experiments demonstrated that the technique is capable of detecting even small quantities of 
aggregates and that the species present after dilution to picomolar sample concentrations are 
highly representative of those present at the higher concentrations under which aggregation 
readily takes place (600 nM – 2 µM) (see Supplementary Dicussion and Supplementary Fig. 
3a,b). 
We first carried out aggregation experiments at a concentration of Aβ140 of 30 nM, a 
value similar to its typical physiological concentration in cerebrospinal fluid (CSF)22. We 
observed the formation of 300 pM of oligomers representing approximately 1% of the total 
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number of molecules present. This result confirms previous speculation that oligomeric species 
can form at Aβ140 concentrations similar to those in physiological environments but at which 
fibril formation can be very slow23. In order to be able to collect data under concentrations where 
aggregation occurs more rapidly and it where it is possible to conduct bulk experiments and 
single molecule measurements with high signal-to-noise ratios, the concentrations were 
increased either to 600 nM or to 2 µM for further experiments; these experimental conditions 
were also selected as they yielded highly reproducible data. The aggregation experiments at these 
higher concentrations reveal a rise in the population of stable oligomeric species to a peak 
concentration of ~20 nM during the incubation of 2 μM Aβ140 (again representing about 1% of 
the total molecules present) along with a 75% decrease in the monomer concentration during the 
growth phase of fibril formation (Fig. 1a).   
The relative quantities of the different oligomeric forms that could be observed decreased 
exponentially with increasing apparent size under all conditions examined in this study (dimers 
were most abundant; the probability of finding a 10-mer relative to a dimer is ~3000:1). Indeed, 
this distribution of apparent sizes was sustained throughout the progress of the aggregation 
reaction suggesting that many intermediate species are involved in the growth of amyloid fibrils 
(Fig. 1b, Supplementary Fig. 3ce). At these higher concentrations we observe that the 
distribution of stable oligomer sizes is effectively the same as that formed at a concentration of 
30 nM (Fig. 1c). This exponential form of the distribution of apparent oligomer sizes directly 
observed in our experiments has been predicted by theoretical analysis of the aggregation of 
other protein systems, and is consistent with models of both the bulk kinetics and the molecular 
processes of amyloid growth7,24.  
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Characterizing the disaggregation of Aβ140 fibrils 
We then set out to study the species present during the process that is the reverse of 
aggregation into fibrils, their disaggregation. Aβ140 fibrils were formed from monomeric 
peptides at a concentration of 8 µM, pelleted by centrifugation, washed, and finally re-suspended 
in buffer in the absence of any additional Aβ140. Using TCCD, we monitored the release of 
soluble species into the buffer from the fibrils at a rate of (9.3  3.1) ×105 s1 (n=12, s.e.m.) 
(Fig. 1d, see Supplementary Methods for details).  These results are similar to previous 
observations of exchange between amyloid fibrils and soluble proteins25,26.  However, the single 
molecule experiments in the present study additionally reveal that the species released include a 
small population of stable oligomers as well as monomeric species (Fig. 1c). 
After 50 h of disaggregation the concentrations of the various species in solution were 
constant and we could assume that the system had reached equilibrium.  We then derived the 
thermodynamic stabilities of the various species present. The values of ΔGº are 18.2  0.5 kJ 
mol1 for dimers and an average of38.9  2.7 kJ mol1 for the larger oligomers (error values are 
s.d.). These values are in good agreement with previous bulk measurements of the free energy of 
the formation of amyloid fibrils (36 kJ mol1)27.  They also indicate that the dimers are 
inherently less thermodynamically stable than all larger oligomers, and that the stability of the 
larger oligomers is largely independent of their size (Table 1), findings that are consistent with 
previous computational analyses28. 
 
Effect of clusterin on the aggregation of Aβ140 
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The observation of stable distributions of oligomers by cTCCD during the aggregation 
and disaggregation processes of Aβ140 provided a framework for the investigation of interaction 
of clusterin and such ensembles of species. In a series of experiments, we first used unlabeled 
clusterin to explore any changes in the Aβ140 oligomer distribution resulting from the presence 
of the chaperone and then AlexaFluor647-labeled clusterin to characterize the specific 
interactions between clusterin molecules and Aβ140 species. Control experiments confirmed that 
AlexaFluor647-labeled clusterin behaved in a similar manner to its unlabeled counterpart which 
indicates that fluorescent labeling had no marked effect on the properties of clusterin studied in 
this work (Supplementary Fig. 4a). 
Addition of equimolar quantities of clusterin to monomeric Aβ140 prior to the start of the 
aggregation reaction dramatically inhibits the appearance of small oligomeric species, a finding 
that is consistent with bulk measurements showing that clusterin substantially inhibited fibril 
formation (Fig. 2a)29,30. Moreover, when we added clusterin to solutions in which aggregation 
had progressed to a stage where a significant population of oligomers is present, further self-
association of the peptides was halted (Fig. 2b).  At various points throughout the aggregation 
reaction, the fraction of Aβ1-40 peptides that formed oligomers in the absence of clusterin 
matched well with the fraction of Aβ1-40, at these same points, that formed complexes with 
clusterin when it was added to these oligomeric solutions (Fig. 2c). This result indicates that 
clusterin:Aβ complexes are very long-lived, persisting for over 50 h following dilution to 
nanomolar concentrations (Fig. 2d). The binding between clusterin and Aβ oligomers was 
observed not only at concentrations of 2 µM but also at concentrations of 100 nM, conditions 
under which fibrils are not observed to form for days. The clusterin:Aβ complexes formed at 
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these low concentrations were found to persist, after dilution, at picomolar concentrations for 
over 200 h (Supplementary Fig. 4bd). Furthermore, the distribution of the sizes of the Aβ140 
oligomers observed in our experiments was not substantially altered in the presence of clusterin 
(Fig. 3a, Supplementary Fig. 4c). We therefore conclude that the growth of larger aggregates, 
and ultimately amyloid fibrils, is inhibited as a result of the very effective sequestration of Aβ 
oligomers by clusterin molecules. 
 
Effect of clusterin on the disaggregation of Aβ140 fibrils 
Studies of Aβ140 fibril disaggregation in the presence of clusterin reveal that oligomers 
released from the fibrils bind to clusterin molecules resulting in an increase in the total oligomer 
population compared to that observed in the absence of clusterin (Fig. 3b). Our observation of a 
population of oligomers resulting from fibril disaggregation is consistent with the oligomeric 
‘halos’ found around Aβ plaques in a mouse model of Alzheimer’s disease31. This result is also 
in line with studies suggesting clusterin increases the observable oligomer population, perhaps 
because of stabilization of Aβ oligomers by clusterin32. As found under aggregation conditions, 
the complexes between clusterin and the Aβ oligomers observed during disaggregation are very 
long-lived, persisting at nanomolar concentrations for over 50 h (Fig. 2d). In each of these 
complexes, the ratio of clusterin:Aβ had a median value of 1.2  1.1 (interquartile range) 
suggesting that there is a direct correlation between the number of clusterin molecules and the 
number of Aβ peptides in a complex (Supplementary Fig. 5). In addition, the presence of 
clusterin bound to the Aβ fibrils is found to decrease both the rate and the extent of fibril 
disaggregation by inhibiting dissociation into monomers (the rate changes to (17  2.7) × 106 
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s1, n=8, s.e.m. with clusterin from (9.3  3.1) × 105 s1, n=12, s.e.m. without clusterin) (Fig. 
3b,c, Supplementary Fig. 6). Similar binding of chaperones to fibrils and inhibition of their 
disaggregation has been previously observed in experiments with other systems3335. The relative 
change in monomer and oligomer populations was reflected in an increase in the magnitude of 
the free energies of formation of dimers (from 18.2  0.5 to 25.8  2.6 kJ mol1, both s.d.) and 
of larger oligomers (from 38.9  2.7 to 43.9  1.0 kJ mol1 both s.d.) when clusterin is present 
(Table 1). In all aggregation and disaggregation experiments, regardless of the presence or 
absence of clusterin, the distribution of oligomeric species followed an approximately 
exponential decrease with increasing apparent size (Fig. 3a).   
 
DISCUSSION 
The present studies reveal that under the experimental conditions used in this work, 
clusterin binds and sequesters oligomers formed during both the aggregation of Aβ140 
monomers and the disaggregation processes of Aβ140 fibrils thereby inhibiting the further 
growth or dissociation of these oligomers. In the CSF, where aggregation is likely to be of 
particular significance, clusterin is present at concentrations between 20 and 60 nM36, levels in 
excess of those of Aβ140 present between 1 and 10 nM
22, a concentration regime in which stable 
oligomers of Aβ1−40 can be formed, according to our data. Clusterin is, therefore, present under 
normal conditions at levels appropriate for prevention of the formation or growth of oligomers 
and their consequent toxicity29. Additionally, the persistence times measured here for complexes 
between clusterin and Aβ140 oligomers (from 50 h to greater than 200 h) are long enough to 
allow for crucial in vivo processes such as Aβ140 production (~15 h), Aβ140 clearance (~14 h), 
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and astrocytic endocytosis (between 12-24 h)37-39. This is particularly noteworthy considering 
that previous studies have correlated binding of Aβ species by clusterin to the in vivo degradation 
of the peptides29,40,41.  
Our single molecule experiments show that the extracellular chaperone clusterin binds to 
all members of the ensemble of soluble oligomers found to be present during the aggregation and 
disaggregation of Aβ140 in our experiments. In this way, clusterin is able to prevent further 
growth and proliferation of aggregated species and in vivo, is likely to sequester the potentially 
toxic oligomeric species until they can be processed and degraded38,41,42. The methodology 
described in this study that has enabled these data to be obtained should be readily applicable to 
different aggregation conditions and to a wide range of disease-associated peptides and proteins 
and therefore represents a powerful means of probing, at the level of individual molecules, the 
seminal link between protein misfolding, aggregation and disease1. 
In the particular case of the Aβ peptide discussed in this work, the ability of clusterin to 
sequester misfolded and potentially toxic oligomers provides a molecular basis for the recently 
identified genetic association between clusterin and Alzheimer’s disease13,14.  Indeed, any 
perturbations that result in reduced clusterin levels, or in a reduction of clusterin’s ability to form 
stable and long-lived complexes with Aβ oligomers, are likely to increase susceptibility to 
Alzheimer’s disease13,14. 
 
Supplementary Information is linked to the online version of the paper. 
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Table 1. Kinetic and Thermodynamic Parameters 
 
Parameter 
 
Without clusterin (n) 
 
With clusterin (n) 
 
Rate of monomer and oligomer release (s1) 
 
(9.3  3.1)×105 (12) 
 
(1.7  0.3)×105 
(8) 
Rate of clusterin release (s1)  (9.8  0.9)×107 
(3) 
Final concentration of all species  (nM) 270  20 (12) 120  20 (8) 
Final concentration of oligomeric species (nM) 0.16  0.06 (12) 0.42  0.1 (8)
Final soluble clusterin concentration  (nM)  90  14 (3) 
   
 
Aggregation 
 
  
ΔG (dimer) (kJ mol1) 23.0  2.9 (4) 
ΔG (larger oligomer) (kJ mol1) 39.3  3.0 (11) 
 
Disaggregation 
 
  
ΔG (dimer) (kJ mol1) 18.2  0.5 (3) 25.8  2.6 (4) 
ΔG (larger oligomer) (kJ mol1) 38.9  2.7 (12) 43.9  1.0 (12) 
ΔH (dimer) (kJ mol1) 43.8  24.5 (3) 
ΔH (larger oligomer) (kJ mol1) 29.1  0.3 (12) 
ΔS dimer (kJ mol1) 80.8  83.5 (3) 
ΔS larger than dimer  (kJ mol1) 28.3  1.1 (12) 
 
 
The rates were derived from fitting monomolecular dissociation functions to the plots of species 
released as a function of time from disaggregation experiments. All thermodynamic values—free 
energies (ΔG), enthalpies (ΔH), and entropies (ΔS) of formation for various sizes of 
oligomers—were determined from the steady state apparent size distributions of the various 
species. Errors for rate values are s.e.m. and errors for thermodynamic values are s.d. 
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FIGURE LEGENDS 
 
Figure 1 Bulk and single molecule studies of Aβ140. (a) Appearance and disappearance of 
species populated during the aggregation of Aβ140 (2 µM at 37 C with agitation).  Fibril 
formation monitored by thioflavin T (ThT) fluorescence (top). The inset (top) is a transmission 
electron microscopy (TEM) image of the fibrils present after 24 h of incubation (scale bar is 200 
nm). Concentration of soluble oligomers (dimers50mers) (middle), and concentration of 
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monomeric species (bottom) are both tracked using cTCCD. The data are averaged from 
multiple experimental repetitions (2 μM Aβ140, n=3, error bars are s.e.m.). (b) A representative 
distribution of apparent sizes of oligomers formed during Aβ140 aggregation and disaggregation 
(error bars are s.d.). Insets are zoomed into regions of dimers15-mers and 16-mers50-mers to 
provide greater detail. (c) A comparison of the distributions of apparent oligomer sizes during 
aggregation and disaggregation experiments (2 μM Aβ140 aggregation, n=3; disaggregation, 
n=12; 1030 nM Aβ140 aggregation, n=4; error bars are s.e.m.). (d) Time dependence of the 
concentration of soluble species released from a pellet of fibrils (n=12, error bars are s.e.m.). 
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Figure 2 The effects of clusterin on the aggregation 
of Aβ140. (a) Fraction of oligomers detected in 
solution during the aggregation of Aβ140 with and 
without clusterin (Aβ140 and clusterin are both at a 
concentration of 600 nM, n=3, error bars are s.e.m.). 
(b) TIRFM image of the species present after 24 h of 
aggregation of a 2 μM solution of Aβ140 without 
clusterin (left).  TIRFM image of a 2 μM solution of 
Aβ140 after 24 h of aggregation but with 2 µM 
clusterin added 4 h after the start of the reaction, 
during the fibril growth phase (right).  An 
approximately 50% reduction in the average size of 
species present is observed in the presence of 
clusterin (from 1400  200 nm without clusterin to 
780  60 nm with clusterin, s.e.m., P-value is 0.01, 
two-sample independent, two-tailed, t-test). Scale 
bars are 5 µm. (c) Fractions of species formed during 
the aggregation of a 2 μM solution that are 
oligomeric and that are in Aβclusterin complexes. 
(n=3, error bars are s.e.m.). (d) Proportion of 
Aβclusterin complexes persisting at 1020 nM (total 
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peptide concentration) at 21 C. Complexes were formed between clusterin and oligomers from 
both aggregation and disaggregation reactions. For both traces, n=3, error bars are s.e.m. There 
is no statistically significant change in the proportion of complexes with oligomers formed 
during either the disaggregation experiment (P-value of 0.77, ANOVA single-factor) or the 
aggregation experiment (P-value of 0.99, ANOVA single-factor).  
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Figure 3 The effects of clusterin on the 
disaggregation of Aβ140 fibrils. (a) 
Distributions of apparent sizes of oligomers 
formed during aggregation and 
disaggregation reactions with and without 
clusterin. (Aggregation without clusterin, 
n=2, error bars are range; aggregation with 
clusterin, n=3; disaggregation without 
clusterin, n=10; disaggregation with 
clusterin, n=3; error bars are s.e.m.). (b) 
Time dependence of the release of soluble 
species during the disaggregation 
experiments in the presence and absence of 
clusterin (top), increased oligomer 
concentration in the presence of clusterin in 
the concentration plateau region 
(significant with a P-value of 0.002) 
(bottom left) and decreased monomer 
concentration in the presence of clusterin, 
in the concentration plateau region 
(significant with a P-value of 0.0003) 
(bottom right). Both correlations were 
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analyzed using a two-sample independent, two tailed t-test, n=8, and error bars are s.e.m. (c) 
TIRFM imaging of HiLyte488Fluor-labeled Aβ140 fibrils incubated overnight at room 
temperature with AlexaFluor647-labeled clusterin. Aβ140 fluorescence only (left), clusterin 
fluorescence only (middle), and colocalization of the two species (right). Scale bars are 5 μm. 
 
 
 
ONLINE METHODS 
 
cTCCD instrumentation 
 
The instrumentation used in this study has been described previously10. Gaussian laser beams of 
two colors (a tuned diode laser emitting at 488 nm (Spectra Physics, Cyan CDRH) and a helium-
neon laser emitting at 633 nm (Melles Griot, 25LHP151) were overlapped and directed into a 
confocal microscope (Nikon Eclipse TE2000-U) to achieve dual-excitation in the confocal 
volume. The beams then pass through an oil-immersion objective (Appochromat 60x, NA 1.40, 
Nikon) and into the sample with a final beam diameter of approximately 260 nm. The laser 
powers used were 60  5 μW for the 633 nm laser and 50  5 μW for the 488 nm laser and are 
low enough that photobleaching of the fluorophores during their time in the probe volume was 
not appreciable8. During measurements, 200 μL of sample was placed on a 1x1 cm area of a 
BSA-coated glass coverslip (VWR, 631-1339). Then the beam was focused on a confocal plane 
that is 10 μm into the measurement solution, above the coverslip surface.  
 
The fluorescence photons emitted from the sample were collected through the objective, passed 
through a 50 μm pinhole (Melles Griot), separated into the two different detection channels 
(dichroic 585DRLP Omega Filters), and directed to separate avalanche photodiode detectors 
(APDs) (SPCM-AQR-14, Perkin-Elmer Optoelectronics). The APDs feed photon count data in 1 
ms bins into multichannel scalar cards on a personal computer (MCS-PCS, Ortec) which were 
saved for analysis in 600800, 8000 ms frame units. During each measurement, the microscope 
stage was scanned using two orthogonal DC motors (M-112.1DG, Physik 
Instrumente,  Karlsruhe, Germany) across the confocal volume at a constant rate of 200 µm s1. 
See Supplementary Methods for further instrumentation details. 
 
 
TIRFM instrumentation  
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Imaging was performed using total internal reflection fluorescence microscopy (TIRFM) which 
aligns the outputs from a HeNe laser operating at 633 nm (25LHP991230, Melles Griot) and a 
diode laser operating at 488 nm (PC13589, Spectra Physics) and directs them down the edge of a 
TIRF objective (60x Plan Apo TIRF, NA 1.45, Nikon) mounted on a Nikon TE200 microscope. 
Fluorescence collected by the same objective was separated from the returning TIR beam by a 
dichroic (FF500646, Laser2000), split into blue and red components (585 DXLR, Omega 
Optical) and filtered using Dual-View (Optical Insights) mounted filters. The images were 
simultaneously recorded on an EMCCD (Cascade II: 512 Princeton instruments,) whereby the 
EMCCD was split so that each color was recorded on one half of the EMCCD, operating at 70 
C. Data were acquired 7.9 frames s-1 using Metamorph software (Molecular Devices). See 
Supplementary Methods for further instrumentation details. 
 
 
Aβ peptide preparation 
 
Monomeric solutions of HiLyteFluor488 and HiLyteFluor647-labeled Aβ140 (Anaspec) were 
prepared by dissolving the lyophilized peptide in pH 12 NaOH followed by sonication over ice 
for 30 min (Bandelin Sonorex) and subsequent flash freezing into aliquots43. Prior to each of the 
incubations, aliquots of each peptide were brought to pH 7.4 by diluting into SSPE buffer (150 
mM NaCl, 10 mM Na2H2PO4 x H2O, 10 mM Na2EDTA, pH 7.4) to the desired aggregation 
reaction concentration and placed under relevant conditions (e.g. 37 C, agitation). The 
concentration for each labeled peptide was measured before mixing using cTCCD.  
 
 
Preparation and labeling of clusterin 
 
Clusterin was extracted from human serum from Wollongong Hospital (Wollongong, NSW, 
Australia), as described previously44 and labeled using the AlexaFluor647 dye with a 
succinimide linker (Invitrogen). See Supplementary Methods for details. 
 
 
cTCCD and TIRFM data acquisition 
 
For the aggregation experiments, Aβ140 (30 nM to 2 μM) was incubated in SSPE buffer (defined 
above) at 37 C with agitation (200 rpm on a rotary shaker). Samples were taken every 23 hours 
and analyzed using cTCCD. For experiments with clusterin, the chaperone was added at a 1:1 
molar ratio. 
 
For disaggregation experiments Aβ140 fibrils were first prepared by a static incubation of an 8 
μM solution of Aβ140 for 72 h at 37 C. Pelleting and washing were carried out by centrifugation 
at ~10,000×g for 30 min followed by two identical washing steps involving re-suspension of the 
pellet in SSPE buffer and additional centrifugation at ~10,000×g for 2 min; finally the pellet was 
re-suspended in SSPE buffer. The soluble species in the solution were monitored and analyzed 
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using cTCCD. For experiments with chaperones, clusterin and Aβ fibrils were incubated together 
for 1216 h at 21 C and any clusterin that was not bound to fibrils was removed via 
centrifugation (leaving 100200 nM clusterin bound to fibrils). 
 
See Supplementary Methods for details. 
 
 
Quantification of oligomer distributions 
 
The extent of oligomerization of a given sample was tracked by separating bursts coincident in 
both blue and red detection channels from non-coincident bursts. Quantification of oligomer 
distributions for cTCCD measurements was performed by analyzing the brightness of the 
coincident, oligomeric bursts. The brightness in the blue (488 nm) detection channel was 
corrected to account for changes in emission due to FRET between the HiLyteFluor488-labeled 
and HiLyteFluor647-labeled peptides within an oligomer (see Supplementary Methods for 
details). Then the FRET corrected blue channel brightness was scaled by the average burst 
brightness for a blue monomer to yield an average number of blue Aβ molecules in each 
oligomer. These data were then scaled by a factor of two to account for the fact that the blue-
labeled peptides made up only half of the molecules in the aggregating solutions, to find the 
apparent size. Uncertainties in the measurement of this quantity arise from factors that include 
the Gaussian nature of the probe-volume illumination, corrections for the error associated with 
assuming oligomers have equal numbers of red and blue peptides, as well as the inherent 
variation in the number of photons emitted by a single fluorophore. Both Aβ oligomers and 
clusterin-Aβ complexes were treated similarly with respect to the effects of FRET.  
 
Statistical analysis 
 
Statistical tests were performed to determine the significance of changes in distributions of the 
apparent sizes of oligomers as well as the persistence of oligomeric species. In order to compare 
two values, two-sample, two-tailed, independent t-tests were used. For comparison of multiple 
values, ANOVA one-factor tests were used.  
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